Dewpoint Therapeutics
A Boston-based biotech focussed on researching biomolecular condensates to enable drug discovery for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates.
Dewpoint drives drug discovery though a proprietary end-to-end experimental and AI-powered platform.
As of Q1 2023, the company has programs across an varied pipeline spanning oncology, neurodegenerative, cardiopulmonary, and metabolic disease indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer and Novo Nordisk.
Latest Dewpoint Therapeutics News & Features
19 January 2024
14 July 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze